Subject: Repligen Stock Rises
Date: Published: 10/23/91 (33 lines)
Source:  Wall Street Journal.  Copyright Dow Jones & Co. Inc. 

    OTC Focus:
    Stocks Lose Early Gains, Finish Mixed;
    Softness on Big Board and in Bonds Cited
    ----
    By Dave Pettit
    Staff Reporter of the Wall Street Journal

    NEW YORK -- Nervous investors knocked over-the-counter
 stocks off their early highs, leaving the market mixed at the
 close.

[36 lines irrelevant to AIDS removed.  --sysop]

    Among these issues, Repligen yesterday leapt 5 1/4 to 29
 on heavy volume of 2.6 million shares, after gaining 2 3/4
 Monday.  Another is Anergen, which soared 7 1/4 to 27 1/2 on
 1.7 million shares, after rising 4 1/4 a day earlier.  Anergen
 has more than tripled in price since its Oct. 10 initial
 public offering, which was made at $8 a share.
    Repligen has attributed its recent gains to the results
 from tests conducted along with New York Stock
 Exchange-listed Merck on the use of monoclonal antibodies in
 treating AIDS.  After the market closed yesterday, Repligen
 said it will reacquire from Merck the rights to certain AIDS
 compounds.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]